FDA Approves Gilead’s Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal – Gilead Sciences (NASDAQ:GILD)
On Wednesday, the FDA granted accelerated approval for Gilead Sciences, Inc.’s GILD Livdelzi (seladelpar) for primary biliary cholangitis (PBC) in combination with...
